<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">GLADUE, HEATHER</style></author><author><style face="normal" font="default" size="100%">KAPLAN, MARIANA J.</style></author></authors><secondary-authors></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Achilles Tendinopathy After Treatment with Ophthalmic Moxifloxacin</style></title><secondary-title><style face="normal" font="default" size="100%">The Journal of Rheumatology</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2013</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2013-01-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">104-105</style></pages><doi><style  face="normal" font="default" size="100%">10.3899/jrheum.120944</style></doi><volume><style face="normal" font="default" size="100%">40</style></volume><issue><style face="normal" font="default" size="100%">1</style></issue><abstract><style  face="normal" font="default" size="100%">To the Editor:Systemic fluoroquinolones have been known to cause tendinopathy. Since 2008, the US Food and Drug Administration has required a “black-box” warning on all systemic fluoroquinolones because of the risk of tendinopathy and tendon rupture1. Fluoroquinolone-associated tendinopathy symptoms have been documented from as early as 2 hours after the initial exposure to as late as 6 months after discontinuation of therapy2. However, in contrast to systemic fluoroquinolones, no reported cases of tendinopathy have been associated with the use of ophthalmic fluoroquinolones. Further, there is no black-box label for this formulation. We describe a case of tendinopathy following topical ophthalmic fluoroquinolone treatment.A 56-year-old man with a history of hypothyroidism and cataracts underwent cataract surgery and was administered daily moxifloxacin ophthalmic drops. On day 14 of … Address correspondence to Dr. Gladue; E-mail: hgladue{at}med.umich.edu</style></abstract></record></records></xml>